IDH2 and acute myeloid leukemia: A confirmatory Phase 3 study to clarify the role of adding enasidenib to induction/consolidation chemotherapy for IDH2-mutated AML is under evaluation, in a randomized phase 3 multi-institutional trial (NCT#03839771), which importantly will also include a maintenance component of enasidenib (vs placebo) after completion of induction/consolidation (+/− allogeneic SCT) to investigate the role of enasidenib as maintenance.